A New Superbug – Candida Auris

A new superbug may be emerging, and scientists are concerned about it. The global spread of a new superbug could be catastrophic, as we’ve learned from the COVID-19 pandemic.

In most public places during the COVID-19 pandemic, you cannot enter without a mask. The pandemic has brought concerns about the spread of diseases to the forefront for us all, especially when we have no apparent measures (or no sufficient ones) to treat the diseases they threaten us with.

Pick Up Over 8% Yield-to-Maturity with Mallinckrodt International, Bonds Mature April 2023

This week, Durig Capital looks to the healthcare sector where a specialty pharmaceutical company has posted solid back-to-back quarters resulting in increased guidance for 2018. As a result of Mallinckrodt Pharmaceuticals’ performance in both Q1 and Q2, company management has raised 2018 guidance citing solid performance across its product lines. Some of the highlights from Mallinckrodt’s Q2 numbers include:


  • Q2 cash flows from operating activities grew by 17.6% over the same period last year.

  • Net sales increased 5.3% year-over-year.

  • Adjusted Gross Profit increased by 8.4%

  • Year-to-date debt reduction of $535.2 million

  • Interest coverage over 2x for the first six months of 2018.